Oncol Rep 37: [Related article:] 2819-2828, 2017; DOI:
10.3892/or.2017.5510
Subsequently to the publication of the article, the
authors have realized that some errors were contained therein that
went uncorrected before the paper was sent to press. First,
Fig. 4 contained a pair of data
panels that had been misplaced: The LY294002, PC-3 data panel in
Fig. 4A showed the same data as the
RWPE-1, control panel in Fig. 4B,
and the LY294002, RWPE-1 data panel showed the same data as the
matrine, control panel in Fig. 4B.
These errors arose inadvertently during the process of
re-organizing the layout of the figure; a corrected version of
Fig. 4, showing the correct data
panels for the LY294002, PC-3 and LY294002, RWPE-1 experiments in
Fig. 4A and B respectively, is
shown on the next page. Also note that the data shown in Fig. 4C and E have been re-calculated on
the basis of the correction of the data in this Figure, and the
revised histograms are also shown in these Figure parts. In view of
these corrections, in the “Matrine induces cell apoptosis by
increasing Bim and Bax and decreasing Bcl-2 protein levels in
prostate cancer cell lines” subsection of the Results section
towards the bottom of p. 2822, in the penultimate sentence, the
text “...LY294002 resulted in 25.88% cell apoptosis in the PC-3
cells and 18.88% in the RWPE1 cells, compared to 3.11 and 6.89%,
respectively, with LY294002 treatment only (Fig. 4A-D).” should be corrected to:
“...LY294002 resulted in 25.88% cell apoptosis in the PC-3 cells
and 18.88% in the RWPE1 cells, compared to 10.94% and 6.89%,
respectively, with LY294002 treatment only (Fig. 4A-D).” (the changed datum is shown in
bold). Note that the corrected data shown in Fig. 4, and the revision made to the
Results section, do not affect the overall conclusions reported in
the paper. The authors thank the Editor of Oncology Reports
for allowing them the opportunity to present this Corrigendum, and
apologize and to the readership for any inconvenience caused.
